""We really need this technology to increase the productivity of our pharmaceutical industry and tackle the shortage of labor and talent in that space, because there are still thousands of diseases without a cure, without any treatment options, and there are thousands of rare disorders which are neglected," Aliper said in an interview with TechCrunch. "So we need more intelligent systems to tackle that problem.""
"Insilico's platform ingests biological, chemical and clinical data to generate hypotheses about disease targets and candidate molecules. By automating steps that once required legions of chemists and biologists, Insilico says it can sift through vast design spaces, nominate high-quality therapeutic candidates, and even repurpose existing drugs - all at dramatically reduced cost and time. For example, the company recently used its AI models to identify whether existing drugs could be repurposed to treat ALS, a rare neurological disorder."
Modern biotech offers gene editing and drug design capabilities, yet thousands of rare diseases remain untreated. Executives at Insilico Medicine and GenEditBio identify a chronic shortage of skilled researchers as a primary constraint. Insilico seeks to deliver pharmaceutical superintelligence and launched MMAI Gym to train generalist large language models to match specialist performance. The company aims to build multi-modal, multi-task models able to perform diverse drug-discovery tasks with superhuman accuracy. Insilico's platform ingests biological, chemical, and clinical data to generate target hypotheses and candidate molecules, automates workflows once requiring many chemists and biologists, and enables drug repurposing, reducing time and cost.
Read at TechCrunch
Unable to calculate read time
Collection
[
|
...
]